StockLumo

Bluejay Diagnostics, Inc. (BJDX): Form 8-K filed 2026-11-13

Accepted by EDGAR
2026-11-13 16:05 ET
Event date
2026-11-12
Accession no.
0001213900-26-119686
Original filing
SEC EDGAR filing index

AI summary of the filing text. It can contain mistakes; the original filing is authoritative.

Bluejay Diagnostics reports quarterly results and completes SYMON-II enrollment

Bluejay Diagnostics reported financial results for the quarter ended September 30, 2026, and completed SYMON-II enrollment. It established an alternative cartridge manufacturing site ahead of its contractual deadline. The company estimates existing cash will support operations through the second quarter of 2027; additional financing will be required for longer-term development and commercialization plans.

earningsproductguidance

Items reported

Documents

TypeDescriptionDocument
8-KCURRENT REPORTea0312164-8k_bluejay.htm
EX-99.1PRESS RELEASE, DATED NOVEMBER 12, 2026ea031216401ex99-1.htm

The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.